| scholarly article | Q13442814 |
| P2093 | author name string | Xiaoyan Zou | |
| Sheetij Dutta | |||
| Gary R Matyas | |||
| Zoltan Beck | |||
| Farhat A Khan | |||
| Adrian H Batchelor | |||
| Mark D Langowski | |||
| Andrew J Schrader | |||
| Alexis A Bitzer | |||
| Christopher J Genito | |||
| Kimberly Soto | |||
| Merricka C Livingstone | |||
| Monica L Martin | |||
| Sri Hadiwidjojo | |||
| P2860 | cites work | Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein | Q27310086 |
| Nanoscale protein assemblies from a circular permutant of the tobacco mosaic virus | Q27658260 | ||
| A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants | Q28278852 | ||
| Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites | Q28541281 | ||
| Conformational dynamics and antigenicity in the disordered malaria antigen merozoite surface protein 2 | Q28543881 | ||
| Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity | Q30039112 | ||
| A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group | Q44174498 | ||
| First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children | Q46182948 | ||
| Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up | Q46389803 | ||
| Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein | Q47161602 | ||
| Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies | Q47341472 | ||
| Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection | Q47372765 | ||
| Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum | Q47881328 | ||
| Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine | Q48004555 | ||
| Crystal structure of an NPNA-repeat motif from the circumsporozoite protein of the malaria parasite Plasmodium falciparum | Q48021417 | ||
| Strain variation in the circumsporozoite protein gene of Plasmodium falciparum | Q48351091 | ||
| Clonal selection drives protective memory B cell responses in controlled human malaria infection | Q49913937 | ||
| A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. | Q52350559 | ||
| A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. | Q53700367 | ||
| From human antibody structure and function towards the design of a novel Plasmodium falciparum circumsporozoite protein malaria vaccine | Q56380667 | ||
| Plasmodium vivax CS peptides display conformational preferences for folded forms in solution | Q56446985 | ||
| Cryo-EM structure of circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts | Q57479092 | ||
| Evaluation of Assays to Assess the Modulation of Dendritic Cells Functions by Therapeutic Antibodies and Aggregates | Q64106814 | ||
| Epitope-Specific Serological Assays for RSV: Conformation Matters | Q64108972 | ||
| Down-selecting circumsporozoite protein-based malaria vaccine: A comparison of malaria sporozoite challenge model | Q64374845 | ||
| Hypercross-linking surface IgM or IgD receptors on mature B cells induces apoptosis that is reversed by costimulation with IL-4 and anti-CD40 | Q71616325 | ||
| Structure-Based Vaccine Antigen Design | Q91255522 | ||
| Comparison of immunogenicity and safety outcomes of a malaria vaccine FMP013/ALFQ in rhesus macaques (Macaca mulatta) of Indian and Chinese origin | Q91493616 | ||
| Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein | Q91656347 | ||
| A proof of concept for structure-based vaccine design targeting RSV in humans | Q92352452 | ||
| Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ) | Q92449403 | ||
| Structure prediction for CASP8 with all-atom refinement using Rosetta. | Q30380039 | ||
| Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine | Q33577093 | ||
| Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus | Q33876183 | ||
| Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint | Q34036184 | ||
| A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate | Q34232909 | ||
| Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes | Q34249872 | ||
| A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts | Q34261339 | ||
| Conformational preferences of synthetic peptides derived from the immunodominant site of the circumsporozoite protein of Plasmodium falciparum by 1H NMR. | Q34276542 | ||
| IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice | Q34400813 | ||
| Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study | Q34530710 | ||
| The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection | Q34684347 | ||
| Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice | Q34700810 | ||
| Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection | Q34990090 | ||
| P. falciparum and P. vivax Epitope-Focused VLPs Elicit Sterile Immunity to Blood Stage Infections | Q35561160 | ||
| Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies | Q36024455 | ||
| Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains | Q36053524 | ||
| Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine | Q36353548 | ||
| Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine | Q36603519 | ||
| Comparative population structure of Plasmodium falciparum circumsporozoite protein NANP repeat lengths in Lilongwe, Malawi | Q36932032 | ||
| Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults | Q36978351 | ||
| Genetically engineered Tobacco mosaic virus as nanoparticle vaccines | Q37077649 | ||
| High-resolution comparative modeling with RosettaCM. | Q37263048 | ||
| Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. | Q37293748 | ||
| Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses | Q37402846 | ||
| Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes | Q37696415 | ||
| Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns | Q37800358 | ||
| Nanoparticle vaccines | Q38167942 | ||
| Adoption of the 2A Ribosomal Skip Principle to Tobacco Mosaic Virus for Peptide Display | Q38681880 | ||
| Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. | Q38735533 | ||
| Towards an optimized inhibition of liver stage development assay (ILSDA) for Plasmodium falciparum | Q39320768 | ||
| High-level systemic expression of conserved influenza epitope in plants on the surface of rod-shaped chimeric particles | Q39396533 | ||
| A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types | Q40836430 | ||
| Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes | Q40933066 | ||
| IgM-mediated B cell apoptosis. | Q41134201 | ||
| Presentation of peptides from Bacillus anthracis protective antigen on Tobacco Mosaic Virus as an epitope targeted anthrax vaccine | Q41171203 | ||
| T-dependent B cell responses to Plasmodium induce antibodies that form a high-avidity multivalent complex with the circumsporozoite protein. | Q41349538 | ||
| Valency and density matter: Deciphering impacts of immunogen structures on immune responses against a tumor associated carbohydrate antigen using synthetic glycopolymers | Q42534609 | ||
| Simulation of B cell affinity maturation explains enhanced antibody cross-reactivity induced by the polyvalent malaria vaccine AMA1. | Q42795407 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P921 | main subject | Plasmodium falciparum | Q311383 |
| tobacco mosaic virus | Q332874 | ||
| P304 | page(s) | 3114-3122 | |
| P577 | publication date | 2020-01-27 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform | |
| P478 | volume | 117 |
Search more.